Benefix
Hemophilia B
PfizerPhase 4 / ApprovedDormant
A
83/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 85/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Hemophilia B cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eptacog Alfa AryoGen Pharmed Co. | Phase 4 | A |
Factor Ix CSL Behring | Phase 4 | A |
Nonacog Beta Pegol Novo Nordisk A/S | Phase 3 | A |
Factor Ix CSL Behring | Phase 4 | BBB |
Coagulation Factor Viia American Thrombosis and Hemostasis Network | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Benefix is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →